Lowest Price Guaranteed
Pages
321
Last Updated
April 2026
View Count
17962
The spatial genomics and transcriptomics market, valued at USD 6.5 billion in 2025, is projected to reach USD 7.3 billion in 2026 and USD 20.1 billion by 2035, with a 11.9% CAGR during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
Since the discovery of the first human genetic map in 1987, the field of omics-based analysis has evolved significantly. Researchers have focused their efforts from decoding the primary sequence of genes to analyzing the location and interaction of cell types, and biomarkers (primarily, DNA, RNA and proteins), through a process known as spatial phenotyping. The traditional molecular profiling analytical techniques, such as microarrays quantitative polymerase chain reaction (qPCR), flow cytometry, mass spectrometry, immunohistochemistry and enzyme linked immunosorbent (ELISA) assay, though widely adopted, are known to dissociate the tissue samples, thereby causing loss of critical spatial multi-omics information across the genome, transcriptome, and proteome. This unmet need in the life sciences research market has prompted innovators to amalgamate cell imaging and molecular profiling techniques to enable visualization, as well as high-throughput quantification of the cells and biomarkers within the tissue samples.
 |
 |
 |
The solutions (that include platforms, along with affiliated reagents and software applications) enable the researchers to further advance and scale their research, by offering a better understanding of the disease morphology, discover novel biomarkers and develop precision therapies. Additionally, these spatial phenotyping platforms can be seamlessly integrated with the current NGS-workflows. Therefore, the adoption of these novel devices to scale research from discovery to translational and clinical phases, is on the rise. In fact, according to a recent survey, approximately 44% of respondents expressed their intent to purchase a spatial profiling platform. In the same year, a research study, published in JAMA Oncology, emphasized the superiority of spatial phenotyping methods for the biomarker analysis in patients suffering from immuno-oncological diseases. Further, Nature Methods dubbed Spatial Transcriptomics as “Method of the Year” for 2020.
In order to capitalize the growing opportunity within this niche market, the developers of spatial genomics and transcriptomics solutions are engaged in efforts to improve the penetration of their proprietary technologies, within the diverse client base, including academic research centers, research institutes and biopharma companies. As a result, they are engaged in incorporating advanced features to their devices, including machine learning-based image analysis, automated sample processing, high-multiplexing, and biomarker-specific gene panels (including those associated with SARS-CoV-2). At the same time, the cost of running these complex tests has dramatically decreased in recent years; the spatial analysis of high-plex stained panels now costs USD 1,000 per slide, which is similar to the cost of whole genome sequencing by next generation sequencing. Further, these instruments are designed to be capable of processing formalin-fixed paraffin embedded (FFPE) tissue sample. This feature is important because nearly 80% of the translational research studies, that use tissue samples, are dependent on the aforementioned sample type. Few players have also introduced customized access programs for biopharmaceutical players, enabling them to leverage spatial omics technologies, for the purpose of guiding their drug development programs. Driven by the growing adoption and continuous innovation of spatial biology solutions, we are led to believe that the opportunity for spatial profiling solution providers is likely to witness a sustained market growth over the forecast period.
The overall spatial genomics and transcriptomics market is segmented into instruments, consumables and services. Our estimates suggest that the due to the relatively higher price of instruments, the market is likely to be driven by the revenues generated through the sales of spatial-omics instruments and this trend is unlikely to change in the foreseen future. Further, the expanding instrument base is likely to drive recurring reagents and software revenue stream; as a result, the share of consumables and software segment is expected to grow at a relatively faster pace.
This section distributes the overall spatial genomics and transcriptomics market revenues across the sample type analyzed, which includes proteins, RNA and DNA. In January 2024, Akoya Biosciences and Thermo Fisher Scientific announced a licensing and distribution agreement allowing Akoya to market the combination of its spatial biology solutions with the Thermo Fisher ViewRNA In Situ Hybridization Assays, for detection of protein and RNA biomarkers in tissue samples.
This section segments the spatial genomics and transcriptomics market on the basis of the end users that are employing various spatial omics solutions; these include pharmaceutical and biotechnology companies, and academic and research institutes. The maximum revenue share (90%) of the current market is generated through the sales of spatial omics solutions to pharmaceutical and biotechnology companies. This can be attributed to the fact that big pharma is evaluating several spatial omics platforms that can be seamlessly integrated into their process workflows for more accurate biomarker identification to advance their preclinical and clinical drug candidates.
The overall spatial genomics and transcriptomics market is segmented on the basis of research areas targeted by the spatial solutions; these pertain to various therapeutic areas, namely into oncological / immuno-oncological disorders, immunological disorders, neurological disorders, infectious diseases and others. Presently, owing to the heightened focus and significant investment dedicated to the discovery of predictive biomarkers in oncology and immuno-oncology, the maximum revenue generation potential is associated with projects intended for the spatial detection of tumor microenvironment and this trend is unlikely to change in future.
 |
 |
 |
This segment highlights the distribution of spatial genomics and transcriptomics market across various geographies, namely North America, Europe, Asia-Pacific and Rest of the World. According to our projections, North America currently captures nearly half of the overall market share. Further, owing to the increasing patient recruitment for biomarker-based clinical trials and growing number of contract manufacturing companies for medical devices in the Asia-Pacific region, the market is likely to grow at a relatively faster pace, during the given time period.
The spatial genomics and transcriptomics market is anticipated to grow at CAGR of 11.9% during the forecast period. The market size is estimated to reach $ 20.1 billion by 2035. The rise will primarily be driven by the paradigm shift from broad-spectrum interventions to biomarker-targeted drugs and diagnostics. Further, the expanding applications of spatial omics solutions, from research domains like cancer, neuroscience, and immunology to translational and clinical phases, is expected to fuel further growth. Additionally, the increasing adoption of integrated omics technologies, including genomics and proteomics, is anticipated to play a pivotal role in driving market expansion.
The spatial genomics and transcriptomics market has seen an increase in partnership activity, growing at a CAGR of over 70%. This trend underscores the growing interest among solution providers to diversify their product portfolios and enhance the capabilities of existing instruments. Notably, integration agreements for spatial omics solutions with contemporary staining assays/reagents constitute a significant portion, accounting for 18% of total deals since 2016. In January 2024, AtlasXomics and EpiCypher partnered to develop CUT&Tag kits and assay services for spatial epigenomics applications. In February 2024, DNAnexus and Curio Bioscience teamed up to streamline data analysis for large-scale spatial transcriptomics projects, enabling customers of Curio Seeker Spatial Mapping Kit to utilize DNAnexus Precision Health Data Cloud for processing unbiased datasets across various tissue types and species.
Moreover, the landscape is marked by a substantial intellectual property presence, with over 500 patents/patent applications globally, highlighting the intense research and development efforts ongoing in the market.
Over 72% of the companies offering spatial genomics and transcriptomics solutions are headquartered in North America, followed by companies based in Europe. Further, close to 50% of the global market for spatial omics solutions is anticipated to be captured by companies based in North America; this trend is likely to remain the same in future as well. In March 2024, Lunaphore (the swiss subsidiary of Bio-Techne), partnered with Nikon Instruments to expand access to spatial biology contract services in the US by deploying Lunaphore's Comet spatial instrument at Nikon's BioImaging Lab in Boston.
Examples of key companies engaged in spatial genomics and transcriptomics market (which have also been profiled in this market report; the complete list of companies is available in the full report) include 10x Genomics, Akoya Biosciences, Bruker, Canopy Biosciences, Lunaphore Technologies, Molecular Machines & Industries (MMI), Resolve Biosciences, NanoString Technologies and Vizgen. This market report includes an easily searchable excel database of all the companies providing spatial genomics and transcriptomics solutions, worldwide.
Several recent developments have taken place in the field of spatial genomics and transcriptomics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Spatial Genomics and Transcriptomics Market: Industry Trends and Forecasts, till 2035” market report offers an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the spatial genomics and transcriptomics market. The market research report underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in spatial genomics and transcriptomics. Amongst other elements, the market report includes:
 |
 |
 |
The key objective of spatial genomics and transcriptomics market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for spatial genomics and transcriptomics market during the forecast period. We have developed informed estimates on the evolution of the market for the forecast period till 2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across different segments; type of solution (instruments, services, consumables and software), type of sample analyzed (DNA, RNA and proteins), end user (academic research institutes and pharmaceutical companies), research areas (oncology, immunology, neurology, infectious and others), and key geographical locations (North America, Europe and Asia- Pacific and the Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry’s growth.
The opinions and insights presented in the market research report were influenced by discussions held with several stakeholders engaged in spatial genomics and transcriptomics. The market report features detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.